WASHINGTON D.C —
Kwararu sun bayyana cewa, za a iya amfani da wata irin kwayar rigakafin HIV dake tsayar da kwayar cutar kanjamau daga shiga cikin wurin kariyar jiki, wajen aiki kan cutar kansa nan gaba, yayinda kamfanonin magani suka hada magunguna wuri daya.
Masu binciken Amurka sun sami ci gaba a binciken da suke yi kan maganin CCR5 bayan sun gwada maganin kan Beraye. Binciken su ya bada rahoton babbar raguwar cutar kansar nono wadda suka iske cikin berayen da suka gwada.
Masu bincike daga Jami’ar Thomas Jefferson Kimmel, sunce binciken ya bada mamaki. Yanzu wani mai binciken a kamfanin Citi believe Merck & Co Inc yayi kokarin daukar mataki na gaba wajen gwajin wannan maganin CCR5 akan masu cutar kansa. An yi watsi da kokarin amfani da wannan maganin CCR5 a yaki da cutar kanjamau saboda binciken da aka yi a lokacin baya bai yi nasara ba.
Bisa ga cewar kamfanin Citi, Kamfanin Pfizer Inc da Bristol-Myers Squibb wadanda suke da wadannan irin kwayoyin a kamfaninsu, suma zasu bi hanyar gwajin maganin CCR5. Yayinda aka tambaye shi yayi bayani kan gwajin vicriviroc a 2014 kan marasa lafiya a matsayin wani hadi don maganin kansa, mai magana domin kamfanin Merck yace basu da wani shiri kamar haka.
Har yanzu kamfanin Citi kuma yana tunanin yin gwajin maganin vicriviroc domin kariyar cututuka da suka shafi cutar kansa da suka hada da kansar nono da kansar mafitsara da kuma da kansar hanta.
Pfizer ma zasu iya fara gwajin jinyar cutar kansa a da CCR5 Selzentry, maganin da aka yarda da shi, wanda yanzu kamfanoni da yawa suke sayarwa.
A halin da ake ciki, kamfanin Bristol, shi kuma yana mataki na biyu na bincike kan amfani da maganin CCR2/5 wajen amganin cutar sikari da cututtukan koda.
Masu binciken Amurka sun sami ci gaba a binciken da suke yi kan maganin CCR5 bayan sun gwada maganin kan Beraye. Binciken su ya bada rahoton babbar raguwar cutar kansar nono wadda suka iske cikin berayen da suka gwada.
Masu bincike daga Jami’ar Thomas Jefferson Kimmel, sunce binciken ya bada mamaki. Yanzu wani mai binciken a kamfanin Citi believe Merck & Co Inc yayi kokarin daukar mataki na gaba wajen gwajin wannan maganin CCR5 akan masu cutar kansa. An yi watsi da kokarin amfani da wannan maganin CCR5 a yaki da cutar kanjamau saboda binciken da aka yi a lokacin baya bai yi nasara ba.
Bisa ga cewar kamfanin Citi, Kamfanin Pfizer Inc da Bristol-Myers Squibb wadanda suke da wadannan irin kwayoyin a kamfaninsu, suma zasu bi hanyar gwajin maganin CCR5. Yayinda aka tambaye shi yayi bayani kan gwajin vicriviroc a 2014 kan marasa lafiya a matsayin wani hadi don maganin kansa, mai magana domin kamfanin Merck yace basu da wani shiri kamar haka.
Har yanzu kamfanin Citi kuma yana tunanin yin gwajin maganin vicriviroc domin kariyar cututuka da suka shafi cutar kansa da suka hada da kansar nono da kansar mafitsara da kuma da kansar hanta.
Pfizer ma zasu iya fara gwajin jinyar cutar kansa a da CCR5 Selzentry, maganin da aka yarda da shi, wanda yanzu kamfanoni da yawa suke sayarwa.
A halin da ake ciki, kamfanin Bristol, shi kuma yana mataki na biyu na bincike kan amfani da maganin CCR2/5 wajen amganin cutar sikari da cututtukan koda.
